Results 31 to 40 of about 941,442 (284)

Impairments in signaling cascades mediating the progression of liver disease from chronic hepatitis to hepatocellular carcinoma in animal and human models [PDF]

open access: yes, 2011
The most common risk factors for chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC) include chronic alcohol abuse and infection with hepatitis B (HBV) or hepatitis C (HCV) virus.
Setshedi, Mashiko
core   +1 more source

hsa_circ_0006916 promotes hepatocellular carcinoma progression by activating the miR-337-3p/STAT3 axis

open access: yesCellular & Molecular Biology Letters, 2020
Background Circular RNAs (circRNAs) are thought to be involved in the development of various malignancies. The expression and function of hsa_circ_0006916, a newly identified circRNA, in hepatocellular carcinoma remain unclear.
Xiao-Yong Zhou   +5 more
doaj   +1 more source

Basic and Clinical Research Progress of Immunotherapy for Hepatocellular Carcinoma

open access: yesZhongliu Fangzhi Yanjiu, 2023
Primary liver cancer, especially hepatocellular carcinoma, poses a serious threat to the life and health of the Chinese people. Given the insidious onset of liver cancer, less than 30% of hepatocellular carcinoma patients are considered for radical ...
ZHANG Zechuan, SUN Beicheng
doaj   +1 more source

Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease [PDF]

open access: yes, 2010
Copyright @ 2010 Cancer Research UK. This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.Background: α ...
J Anastassiou   +11 more
core   +1 more source

Spatially resolved visualization of reprogrammed metabolism in hepatocellular carcinoma by mass spectrometry imaging

open access: yesCancer Cell International, 2023
Background Metabolic reprogramming refers to tumor-associated metabolic alterations during tumorigenesis and has been regarded as one of the most important features of cancer.
Bangzhen Ma   +5 more
doaj   +1 more source

Epigenetic reprogramming of lineage switching in cancer

open access: yesFEBS Letters, EarlyView.
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı   +4 more
wiley   +1 more source

METTL21A promotes hepatocellular carcinoma progression via methylating and stabilizing BAG3

open access: yesnpj Precision Oncology
Protein methyltransferases regulate diverse physiological and pathological processes through histone and non-histone substrate methylation. While the role of histone methyltransferases in tumorigenesis is well-established, the contribution of non-histone
Ping Zhan   +11 more
doaj   +1 more source

miR-100 Suppresses the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma Cells via Targeting CXCR7

open access: yesJournal of Immunology Research, 2021
This study is to elucidate the functions of miR-100 in hepatocellular carcinoma progression and to explore the underlying mechanisms. Expression levels of miR-100 in normal-cancer hepatocellular carcinoma tissues were measured using quantitative real ...
Yiman Ge   +5 more
doaj   +1 more source

Ligand‐dependent transcriptional heterogeneity in cell cycle gene expression delays G1/S entry

open access: yesFEBS Letters, EarlyView.
EGF and HRG induce distinct G1/S progression programs in ErbB2‐amplified BT474 breast cancer cells. Despite activating the potent ErbB2–ErbB3 heterodimer, HRG does not accelerate cell‐cycle entry. Instead, EGF promotes earlier restriction‐point passage via ERK–FOS signaling, whereas HRG activates the AKT–MYC axis, driving transcriptional heterogeneity ...
Ririn Rahmala Febri   +5 more
wiley   +1 more source

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma [PDF]

open access: yes, 2010
Background: The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure ...
Pinna, Antonio D.   +402 more
core   +5 more sources

Home - About - Disclaimer - Privacy